Selected References
- Bristol-Myers Squibb. 2019. Available at https://clinicaltrials.gov/ct2/show/record/NCT01087125?view=record
- Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). BioDrugs, 37(1):73-87.
- E.R. Squibb and Sons, L.L.C. (Last updated: October 30, 2023). Orencia drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb.
- Ghalandari N, et al. 2022. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. Br J Clin Pharmacol, 88(12):5378-5388.
- Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum, 45(3):351-356.
- Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs, 71(15):1973-1987.
- National Institutes of Health. (Last updated February 24, 2024). COVID-19 Treatment Guidelines: Abatacept. Available at https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/abatacept/ through August 16, 2024.
- Ojeda-Uribe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol, 32(5):695-700.
- Ostensen M and Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol, 23(3):293-298.
- Partlett R and Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int, 31(4):445-449.
- Pham T., et al. 2012. Abatacept therapy and safety management. Joint Bone Spine, 79 Suppl 1:3-84.
